Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Palisade Bio Inc (PALI)

Palisade Bio Inc (PALI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Palisade Bio, Inc. Appoints Brian G. Feagan, MD, to Clinical Advisory Board Quiver Quantitative, Inc. - Tue Dec 17, 5:56PM CST

Palisade Bio appoints Dr. Brian G. Feagan to its Clinical Advisory Board to enhance its autoimmune therapeutic development.Quiver AI SummaryPalisade Bio, Inc. has announced the appointment of Dr. Brian...

PALI : 1.7500 (-2.78%)
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board GlobeNewswire - Tue Dec 17, 7:30AM CST

PALI : 1.7500 (-2.78%)
Palisade Bio, Inc. Closes $5 Million Underwritten Public Offering to Support Clinical Trial and R&D Efforts Quiver Quantitative, Inc. - Sat Dec 14, 1:24AM CST

Palisade Bio closed a $5 million public offering to fund clinical trials and research for autoimmune and inflammatory diseases.Quiver AI SummaryPalisade Bio, Inc. has successfully closed an underwritten...

PALI : 1.7500 (-2.78%)
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules GlobeNewswire - Fri Dec 13, 3:05PM CST

PALI : 1.7500 (-2.78%)
Palisade Bio, Inc. Announces Pricing of $5 Million Underwritten Public Offering Quiver Quantitative, Inc. - Thu Dec 12, 9:40PM CST

Palisade Bio announces a $5 million public offering to fund its clinical trials and research efforts.Quiver AI SummaryPalisade Bio, Inc. has announced a public offering of approximately $5 million to develop...

PALI : 1.7500 (-2.78%)
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules GlobeNewswire - Thu Dec 12, 11:05AM CST

PALI : 1.7500 (-2.78%)
Palisade Bio Reports No Adverse Events in Phase 1 Study of PALI-2108 for Ulcerative Colitis Quiver Quantitative, Inc. - Tue Dec 3, 5:36PM CST

Palisade Bio reports no adverse events in initial dosing cohorts of PALI-2108 for ulcerative colitis, advancing clinical trials.Quiver AI SummaryPalisade Bio, Inc. announced preliminary results from the...

PALI : 1.7500 (-2.78%)
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects GlobeNewswire - Tue Dec 3, 7:15AM CST

PALI : 1.7500 (-2.78%)
Palisade Bio Presents Promising Preclinical Data for PALI-2108 at 8th Annual Antifibrotic Drug Development Summit, Targeting Fibrostenotic Crohn's Disease Quiver Quantitative, Inc. - Thu Nov 21, 5:36PM CST

Palisade Bio announced promising preclinical results for PALI-2108, targeting fibrotic pathways in Crohn's disease, with enhanced safety profiles.Quiver AI SummaryPalisade Bio has announced promising preclinical...

PALI : 1.7500 (-2.78%)
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC) GlobeNewswire - Thu Nov 21, 7:15AM CST

PALI : 1.7500 (-2.78%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot